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Summary A class of new 5-fluorouracil (FU) analogues, the 5-fluoro-5,6-dihydro-6-alkoxy-uracils was syn-
thesised with a modification at the 6-position of the pyrimidine ring. At this position the analogues have a
hydroxy or alkoxy group of different chain lengths either in the cis- or trans-configuration. The antipro-
liferative effect of these compounds was tested on five cell lines of different origin. Generally, the analogues
with a cis-configuration had a higher activity than those with a trans-configuration. The growth inhibitory
effect of the compounds decreased with increasing alkoxy chain length, but the compound with a hydroxy
group had the lowest growth inhibitory effect. One analogue, cis-5-F-5,6-dihydro-6-methoxy-uracil had a
higher antiproliferative effect than FU in one of the cell lines. Effects on thymidylate synthase (TS), the
possible target of these analogues, were evaluated by thymidine rescue of growth inhibition and incorporation
of tritiated deoxyuridine (3H-UdR) into DNA. In solid tumour cell lines addition of TdR reversed the
antiproliferative effect. Inhibition of TS in intact cells was determined by measuring 3H-UdR incorporation in
two cell lines. The effect of cis-5-F-5,6-dihydro-6-methoxy-uracil on incorporation of 3H-UdR was 2- to 5-fold
stronger than that of FU in both cell lines. All other compounds produced a higher 3H-UdR incorporation
than FU both at equimolar and equi-toxic concentration. Concluding from these results we regard cis-5-F-5,6-
dihydro-6-methoxy-uracil as the most promising FU analogue of this series, because of its higher antipro-
liferative activity than FU and marked inhibition of TS in intact cells.
Since its introduction as an antineoplastic agent 5-
fluorouracil (FU) has been used for the treatment of a wide
spectrum of solid tumours. However, objective response rates
are moderate, being lower than 20% in controlled random-
ised trials of advanced colorectal cancer treatment and cures
are rarely achieved (Weckbecker, 1991; Peters & Van Groen-
ingen, 1991a). Several approaches have been used to increase
this therapeutic index, such as combination with other anti-
cancer drugs, biochemical modulation of the FU metabolism
(Peters & Van Groeningen, 1991a) and synthesis of more
potent analogues (Heidelberger et al., 1983). All these studies
are based on thorough research on the mechanism of action
of FU, that has been performed during the last three decades
(Pinedo & Peters, 1988; Diasio & Harris, 1989; Weckbecker,
1991).
The mechanism of action of FU is rather complicated and
involves conversion to nucleotides. One of the most impor-
tant nucleotides for antitumour activity is 5-fluoro-2'-deoxy-
uridine-5'-monophosphate (FdUMP), which blocks DNA
synthesis through the inhibition of thymidylate synthase (TS,
E.C.2.1.1.45), by the formation of a stable ternary complex
with FdUMP and the cofactor 5,10-methylenetetrahydrofolate.
Other nucleotides, that play a role in FU activity are 5-
fluorouridine-5'-triphosphate (FUTP) and 5-fluoro-2'-deoxy-
uridine-5'-triphosphate (FdUTP). Incorporation of FUTP
into RNA has been associated with both antitumour effect
and gastrointestinal/myeloid toxicity. Whether incorporation
of FdUTP into DNA, leading to DNA strand breaks and
DNA fragmentation, really contributes to the antitumour
effect could not be established until now (Pinedo & Peters,
1988). Supported by findings that a low inhibition of TS in
tumours of patients treated with FU may be related to poor
prognosis (Spears et al., 1988), and that an enhanced anti-
tumour effect seems to be related to a better inhibition of TS
(Swain et al., 1989; Peters et al., 1991b, 1992), TS became an
important target. Further research on TS and its inhibitors,
included biochemical modulation of FU therapy with the
folate cofactor precursor, folinic acid leading to an enhanced
TS inhibition and an increase in the response (Swain et al.,
1989). This has promoted the development of potent ana-
logues of the folate cofactor (Harrap et al., 1989). Research
concentrated to a lesser extent on analogues of FdUMP
(Rode et al., 1990) or nucleotides of FU analogues (Heidel-
berger et al., 1983).
The early studies of FU derivatives were focused on the
direction of FU precursors or prodrugs. These compounds
are supposed to generate their activity by a more selective
conversion to FU and/or its metabolites in tumour tissues.
Examples of this group are floxuridine (5-fluoro-2'-deoxy-
uridine) (Heidelberger et al., 1958), ftorafur (NI-tetra-
hydrofuran-2-yl-5-fluorouracil) (Blokhina et al., 1972) and
doxifluridine (5'-deoxy-5-fluorouridine) (Cook et al., 1979).
These compounds did not show a clear therapeutic advantage
over FU in systemic application (Weckbecker, 1991; Grem,
1990), although for some compounds the most optimal
administration schedule has not (yet) been established (De
Bruijn et al., 1989).
Recently we described the synthesis and in vitro anti-
tumour activity of a series of 5-fluorinated nucleosides
(Visser et al., 1988; Braakhuis et al., 1991). In order to obtain
more potent drugs in the class of fluorinated pyrimidines, we
therefore synthesised a new series ofcompounds based on the
structure of FU. The new analogues have a modification at
the 6-position of the pyrimidine ring. The 5-F-5,6-dihydro-6-
OR-uracil compounds have a R substitution of an hydroxy
or alkoxy group of various chain length either in the cis- or
trans-configuration (Figure 1). The rationale to develop this
new series was to have an analogue that, due to the absence
of a 5,6-double bound, is not directly a target for dihydro-
pyrimidine dehydrogenase (DPD). DPD is an important cata-
bolic enzyme, which inactivates a large part (up to 90%) of a
FU dose in vivo, before it can reach the tumour (Diasio &
Harris, 1989). Chemically the group at the 6-position of the
analogue appeared to be susceptible to substituted, so theo-
retically in cells this could be substituted by the SH-group of
TS. In addition, apart from the fact that the group at the
6-position creates a potentially interesting difference in lipo-
philicity, chemically the trans compound was found to be
more stable than its corresponding cis compound. Finally the
N'H-group is still free and no problem with conversion to
nucleosides and subsequently to nucleotides should theoret-
ically occur. This implies that these compounds are no FU
prodrugs.
This study describes the antiproliferative effect in vitro of
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Figure 1 Schematic presentation of the synthesis and basic structure of 5-F-5,6-dihydro-6-alkoxy-uracil.
these 5-fluoro-5,6-dihydro-6-alkoxy-uracil adducts. Each
compound has also been tested for its capacity to inhibit TS,
the possible target for antitumour effect.
Materials and methods
Synthesis
The basic structure of 5-F-5,6-dihydro-6-alkoxy-uracil and
the synthetic route are shown in Figure 1. The detailed
synthesis of the 5-F-5,6-dihydro-6-alkoxy-uracil compounds,
their conformation and their chemical properties will be de-
scribed elsewhere, together with analysis and further charac-
teristics. In short, the 5-F-5,6-dihydro-6-OAc-uracil adduct is
formed from the reaction of gaseous AcOF with uracil in
acetic acid (Visser et al., 1986). Under acidic conditions
(H2SO4) reaction of the 5-F,6-OAc adduct with ROH resulted
within 15min at 80°C in predominantly the corresponding
cis-5-F-5,6-dihydro-6-alkoxy-uracil compounds; prolonged
heating increased the amount of the trans compound result-
ing in a cis/trans ratio of about two. After addition of an
aqueous K2CO3 solution until pH = 3, the solvent was roto-
evaporated and the cis/trans compounds were separated by
column chromatography (Lobar Lichoprep. Rp-8, 40-63 ltm
(Merck, Amsterdam, The Netherlands); eluent: ultrapure
water). After collection, the water was removed by freeze-
drying. The cis/trans stereochemistry of each adduct was
established by 'H NMR measurement of the J5F,6H coupling
constant (cis isomers: J5F,6H 2.0-2.3 Hz; trans isomers J5F,6H
7.1-7.4 Hz). Due to anomeric effects (Visser et al., 1986), all
isomers have the preferred conformation with the OR-group
in the axial position.
Drugs
FU was obtained from Sigma (St Louis, MO, USA). All
drugs were dissolved in sterile 0.9% NaCl and stored at
-20°C at 102 mol 1-' stock solution. Under these condi-
tions all compounds were stable for several months.
Cell lines
Two human cancer cell lines were used, UM-SCC- 11B
(doubling time 28 h), a moderately differentiated squamous
cell carcinoma of the larynx and UM-SCC-14C (doubling
time 26 h), a poorly differentiated squamous cell carcinoma
of the oral cavity. Both cell lines were obtained from Dr T.E.
Carey, University of Michigan, Ann Arbor, USA (Carey,
1985). A third cell line C26-10 (doubling time 18 h), was a
gift from Dr Klohs (Klohs & Steinkampf, 1988) and was
originally derived from a undifferentiated murine colon car-
cinoma (Corbett et al., 1975). The two lymphoblastoid cell
lines W1-L2 and WI-L2:Cl (a gift from Dr A.L. Jackman)
have been added to the panel, because the WI-L2:C1 has an
acquired resistance against a folate-based TS inhibitor, which
resulted in a 200-fold overexpression of the TS protein and
TS activity compared to the parental W1-L2 (O'Connor et
al., 1992).
The lymphoblastoid cell lines were grown in RPMI 1640
(Flow Laboratories, Irvine, Scotland). The other cells were
routinely grown in Dulbecco's modified Eagle's medium
(DMEM, Flow). DMEM and RPMI medium were supple-
mented with 10% heat inactivated foetal calf serum (FCS)
(Gibco, New York, USA), and 1 mM L-glutamine. During
experiments 100 U ml-' penicillin and 100 gig ml-' strepto-
mycin were added to the culture medium.
Growth inhibition tests
Cells from routine, subconfluent cultures were transferred to
96-well flat-bottom plates (Greiner Labortechnik, Solingen,
Germany) (C26-10, UM-SCC-1 lB and UM-SCC-14C) or
round-bottom plates (Greiner) (Wl-L2 and WI-L2:Cl). For
the UM-SCC-I1B and UM-SCC-14C cell density was 1500
cells/well in 150gil medium. After a lag-phase of 72 h, 50gil
of drug containing medium was added. C26-10 cells were
plated at a density of 1000 cells/well in 100 gil and after 24 h
1001il drug containing medium was added. W1-L2 and Wl-
L2:C1 were seeded at a density of 10,000 cells/well in 50gil
and 1 h later 50gil drug containing medium was added. For
the thymidine (TdR) rescue experiments 10 giM (final concen-
tration) was added simultaneously with FU or one of the
analogues. Drug exposure time was 72 h for all cell lines. The
drugs were tested in triplicate at concentrations ranging from
10-' to 10-8 M. Growth inhibitory effects were evaluated
with the standard sulforhodamine B (SRB) assay (Skehan et
al., 1990; Keepers et al., 1991) for C26-10, UM-SCC-1 B and
UM-SCC-14C and with the MTT assay (Pieters et al., 1988)
for W1-L2 and WI-L2:Cl. The IC50 was the concentration
that corresponded to half-maximal growth of the control
based on the difference of optical density values at the start
and the end of drug exposure. The IC50 concentrations were
determined from at least three separate experiments.
Thymidylate synthase assay
The activity of the enzyme TS was measured with two assays,
a ligand binding assay with [6-3H1-FdUMP (Moravek, Brea,
CA, USA; 20 Ci mmol-'), with which the free FdUMP bind-
ing sites of TS can be determined. The catalytic activity of
the enzyme was determined by measurement of the conver-
sion of [5-3H1-dUMP into dTMP and 3H20 at two substrate
concentrations of dUMP, 1 and 10 giM. In this assay we
evaluated the inhibitory effect of 10 nM FdUMP. Both the
FdUMP binding assay and the 3H-release assay were per-
formed on 7000g supernatants of sonicated cell extracts of
20 x 106 cells. Appropriate controls for determination of
linearity with time and protein were included. Details of the
assay procedure have been described extensively elsewhere
(Peters et al., 1986; Van der Wilt et al., 1992).
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Incorporation of[6-3H]-deoxyuridine into DNA
The incorporation of [6-3H]-deoxyuridine (3H-UdR) (Amer-
sham International, Buckinghamshire, UK; specific activity
17 Ci mmol-1) into DNA was measured in two of the solid
tumour cell lines with the lowest and highest TS activity,
UM-SCC-14C and C26-10, respectively. Two concentrations
of each 5-F-5,6-dihydro-6-alkoxy-uracil compound were test-
ed and compared to the effect of FU. All compounds were
tested at the concentration causing 50% growth inhibition
(equi-toxic) and at the equimolar concentration of 1 gM. The
assay was performed as described previously (Peters et al.,
1987; Braakhuis et al., 1991). Cells (105/well in 100 p1) were
seeded in 96-well filtration plates coated with a hydrophilic
PVDF filter with 0.22 ym pore size (Millipore Corporation,
Bedford, MA, USA). After 24 h 100p1l drug containing
medium was added and the cells were incubated with the
drug for 1 h. Then 10p1l 10IlM 3H-UdR (0.5 ,uCi; specific
activity 4.5 Ci mmol 1) was added. After another 2 h incuba-
tion the plate was put on a Millipore vacuum holder and the
medium was filtered through the membrane of the wells using
a vacuum pump. Next, the cells were precipitated by addition
of 200 p1 ice-cold 8% trichloroacetic acid (TCA), followed by
three washes with 8% ice-cold TCA, four washes with water
and subsequently with 70% ethanol (4 x). After drying by
cold air the filters were collected with a multiple punch
assembly (Millipore), and 500 pl 2 M NaOH was added to
solubilise the precipitated nucleic acids. Finally radioactivity
was counted after addition of 5 ml Optiphase III (Hisafe)
liquid scintillation fluid (LKB, Woerden, The Netherlands).
Values were corrected for non-specific binding of 3H-UdR.
Results
Growth inhibition
The antiproliferative effect of the 5-F-5,6-dihydro-6-alkoxy-
uracil compounds compared to FU in the three solid tumour
cell lines has been summarised in Figure 2. All compounds
were tested on UM-SCC-14C and UM-SCC- IIB, because of
previous testing of fluoropyrimidine analogues in these cells
(Braakhuis et al., 1991). Besides this, because of different
sensitivity for FU, these cell lines form a good model to get
an insight in the spectrum of activity of the new drugs.
FU appeared to be the most active drug in these two cell
lines. In general the analogues with a cis-configuration (the
UM-SCC-1 1B UM-SCC-14C
odd numbers 1-7) had a higher growth inhibitory effect than
the analogues with a trans-configuration (the even numbers).
The antiproliferative effect of the compounds decreased with
increasing chain length of the alkoxy substitution, which was
illustrated by the step-like pattern of compounds number 2,
4, 6 and 8 (Figure 2). Cis-5-F-5,6-dihydro-6-hydroxy-uracil(9)
showed a very poor growth inhibitory effect in these two cells
lines.
For C26-10 (Figure 2), the third solid tumour cell line in
the panel only cis-5-F-5,6-dihydro-6-methoxy-uracil(l) and
cis-5-F-5,6-dihydro-6-ethoxy-uracil(3), the most promising
active compounds from the previous growth inhibition tests,
were tested. Cis-5-F-5,6-dihydro-6-hydroxy-uracil(9) was in-
cluded as a negative control, in view of its very low activity
in the other two cell lines. Interestingly, the analogue cis-5-F-
5,6-dihydro-6-methoxy-uracil(l) had a striking effect on C26-
10, with a better growth inhibition than FU at equimolar
concentration.
Additionally TdR rescue experiments were performed to
evaluate whether growth inhibitory effects mediated by TS,
could be circumvented by the addition of 10 gM TdR. For
these experiments we included the lymphoblastoid cell lines
in the panel. WI-L2:Cl, which has a very high TS expres-
sion, might be a good cell line to study TS related growth
inhibition. Results on the TdR rescue are summarised in
Table I. The dose modifying factor (IC50 of drug+TdR/IC50
of drug alone) varied for each compound and the cell line.
Generally TdR rescued growth inhibition mediated by all
compounds in UM-SCC-1 lB, UM-SCC-14C and C26-10
(except compound no. 9), although not always the level of
significance was achieved. The lymphoblastoid cell lines did
not differ very much with respect to their sensitivity for FU
and the analogues (Figure 2) and TdR rescue was very
limited in these cell lines (Table I).
Thymidylate synthase activity
The activity of TS was measured firstly as the number of
binding sites to TS for FdUMP, the active nucleotide of FU
and secondly as the catalytic activity to convert its natural
substrate dUMP to dTMP. The results of both assays, mea-
sured in cells that were not exposed to FU, were very
different for each cell line (Table II). The FdUMP binding
capacity of the fast growing C26-10 cell lines was about
4-fold higher than that of UM-SCC-11B and about 20-fold
higher than that of UM-SCC-14C. For the catalytic activity
C26-10 W1-L2 W1-L2:C1
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Figure 2 In vitro growth inhibitory effects of the new FU analogues expressed as relative IC50 as compared to the IC50 of FU
(I.I +0.4jiM for UM-SCC-14C, 5.6± 1.2gM for UM-SCC-l lB, 0.63±0.194M for C26-10, 5.7± 1.2gM for W1-L2 and 4.8± 1.1 tM for Wl-L2:C1). Values are means of at least three experiments± s.d. I = cis-5-F-5,6-dihydro-6-methoxy-uracil; 2 = trans-5-F-
5,dihydro-6-methoxy-uracil; 3 = cis-5-F-5,6-dihydro-6-ethoxy-uracil; 4 = trans-5-F-5,6-dihydro-6-ethoxy-uracil; 5 = cis-5-F-5,6-di-
hydro-6-n-propoxy-uracil; 6 = trans-5-F-5,6-dihydro-6-n-propoxy-uracil; 7 = cis-5-F-5,6-dihydro-6-i-propoxy-uracil; 8 = trans-5-F-
5,6-dihydro-6-i-propoxy-uracil; 9 = cis-5-F-5,6-dihydro-6-hydroxy-uracil. Statistics (Student's t-test for unpaired data); in UM-SCC-
1 B the following compounds had a significantly smaller antiproliferative effect than FU, no. 5, P<0.02; no. 6, P<0.05; no. 8,
P<0.01 and no. 9, P<0.001. In UM-SCC-14C FU was significantly more active than the trans-5-F-5,6-dihydro-6-alkoxy-uracii
compounds (no. 2, 4, 6, P<0.05; no. 8, P<0.001; no. 9, P<0.01). In C26-10 compound no. 1 was significantly more active than
FU (P<0.001), while the other two, compounds no. 3 and 9 were less active than FU (P<0.001). In WI-L2 and Wl-L2:Cl
compound no. 9 was significantly less active than FU (P<0.001).5-FLUOROURACIL ANALOGUES IN VITRO 705
Table I Thymidine rescue of antiproliferative effects
UM-SCC-IIB UM-SCC-14C C26-10 Wl-L2 WJ-L2:CJ
dose modifyingfactora
FU 2.0±0.7 (4)b 3.5±1.5 (3) 1.5±0.4 (4)b 0.9±0.1 (4) 1.6±0.5 (4)
no. 1 2.1 ± 1.2 (4) 4.8± 2.6 (4)b 1.3 ±0.2 (5)b 2.2± 1.7 (4) 0.9±0.2 (5)
no. 3 1.4±0.9 (4)b 2.8± 0.6 (3)b 1.4±0.2 (5) 1.0±0.3 (4) 1.2±0.5 (5)
no. 9 2.2±1.3 (4) 3.1±1.7 (3) 1.1±0.3 (4) 1.0 (1) 1.0±0.0 (2)
Values aremeans± s.d. TheTdRconcentration was 10 ,M. aDosemodifyingfactorIC50/IC50of
drug alone. bSignificant rescue by addition ofTdR (P<0.05, paired Student's ttest) (see Figure2
for compound number and name).
Table II FdUMP binding and catalytic activity of thymidylate synthase
UM-SCC-14C UM-SCC-IIB C26-10
FdUMP binding (fmol 10-6 cells)
23±9 122±63 522± 103
Catalytic activity (pmolh-' 10-6 cells)
atILmdUMP 15±13 98±59 231±110
at 10LM dUMP 57± 37 368± 225 1052±244
inhibition by 10 nM FdUMP (pmolh-' 10-6 cells) (% ofcontrol)
at 1 JAM dUMP
at 10gM dUMP
4.8±2.5(32%) 19±13 (19%) 65±37 (28%)
21±17 (36%) 141±98 (38%) 449±123(42%)
Valuesare means±s.d., n = 3. Protein content ofthecellswas6370,7260and
6970yg protein 10-6 cells for UM-SCC-14C, UM-SCC-IlB and C26-10,
respectively.
differences of comparable magnitude were observed between
the cell lines. Finally the addition of FdUMP in the 3H-
release assay inhibited the TS catalytic activity for about
70% in all three cell lines at both substrate concentrations.
Data on catalytic activity of W1-L2 and W1-L2:Cl were
published by O'Connor et al. (1992) (13,400 and 2,410,000
pmol h-' mg-' protein, respectively).
3H-UdR incorporation
In order to determine whether these compounds exerted their
antiproliferative effect through the inhibition of TS, we
measured the incorporation of 3H-UdR into DNA. [6-3H]-
UdR is converted into [6-3H]-dUMP, followed by a TS cata-
lysed formation of [6-3H]-dTMP, one of the precursors for
DNA synthesis. Inhibition of TS reduced the amount of 3H
incorporated into DNA of both UM-SCC-14C cells (Figure
3) and C26-10 cells (Figure 4) with a relatively low and high
TS activity, respectively.
The analogues were tested at a concentration of I .LM. This
is equimolar to the IC50 of FU after 72 h drug exposure in
both cell lines. Although, the drug exposure time in this
assay was only 3 h, exposure to I JAM FU resulted already in
about 50% inhibition of 3H-UdR incorporation, because
inhibition of TS is a fast event and precedes growth inhibi-
tion. Thus this method can be used as a fast screening test
for inhibitory effects on thymidylate synthesis. At the equi-
molar concentration only FU, cis-5-F-5,6-dihydro-6-methoxy-
uracil(1) and cis-5-F-5,6-dihydro-6-n-propoxy-uracil(5) re-
duced 3H-UdR incorporation in UM-SCC-14C (Figure 3a).
At equi-toxic concentration (the IC50 concentration of each
compound after 72 h drug exposure) cis-5-F-5,6-dihydro-6-n-
propoxy-uracil(5) and cis-5-F-5,6-dihydro-6-hydroxy-uracil(9)
produced a reduction of 3H-UdR incorporation into the
DNA of UM-SCC-14C cells comparable to that of FU
(Figure 3b). Three hours incubation of UM-SCC-14C cells
with cis-5-F-5,6-dihydro-6-methoxy-uracil(l) resulted in an
even better reduction of 3H-UdR incorporation than incuba-
tion with FU, during the same period.
In C26-10 cells exposure to cis-5-F-5,6-dihydro-6-methoxy-
uracil(l) at equimolar concentration resulted in an incorpora-
tion significantly lower than control (P<0.05) (Figure 4a).
The other two drugs and also FU did not reduce the 3H-
UdR incorporation at this concentration and short exposure
time. At equi-toxic concentration only cis-5-F-5,6-dihydro-6-
150r-
100l
0
0
0 50- H
FU 1 2 3 4 5 6 7 8
Equimolar concentration
a
9
150 b
0
o 0
0
FU 1 2 3 4 5 6 7 8 9
Equi-toxic concentration
Figure 3 3H-UdR incorporation into DNA of UM-SCC-14C
cells after 3 h exposure to FU and the various analogues at an
equimolar concentration of 1 1M a, or an equitoxic concentration
(IC50 for all compounds) of each of the analogues with 1 LAM for
FU b. Results were expressed relative to control. This is 3H-UdR
incorporation into DNA in the absence of drugs, which was set
at 100%, corrected for non specific effects of 3H-UdR. Control
value for 3H-UdR incorporation was 2.7±1.8 pmol h-' 10-6
cells. Values are means of at least three experiments±s.d. For
names of compound numbers see legend Figure 2. Statistics a,
FU and analogues 1 and 5 had a significantly reduced incorpora-
tion compared to control (P<0.05, Student's t test for paired
data). b, Compounds no. 2, 3, 6, 7 and 8 had a significantly
higher incorporation than FU (P<0.05, Student's t test for
unpaired data).
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Figure 4 3H-UdR incorporation into DNA of C26-10 cells after
3 h exposure to FU and the three analogues at an equimolar
concentration of I tLM or an equi-toxic concentration (IC50 for all
compounds) of each of the analogues compared with 1 timol 1'
for FU. Results were expressed relative to control ( = incorpora-
tion in cells not exposed to drugs). 3H-UdR incorporation into
DNA in the absence of drugs was set at 100%, corrected for non
specific effects of 3H-UdR. Control value for 3H-UdR incorpora-
tion was 1.4± 1.5 pmol h-' 10-6 cells. Values are means of at
least three experiments±s.d. For names of compounds numbers
see legend Figure 2. Statistics no. 1 had a significantly reduced
incorporation compared to control (P<0.05, Student's t test for
paired data) and compared to FU at equi-toxic concentrations
(P< 0.01, Student's t test for unpaired data).
methoxy-uracil(1) produced a 50% reduction of 3H-UdR
incorporation, while the other compounds hardly affected the
incorporation. Generally, at equi-toxic concentrations the
analogues, but also FU had a stronger effect on the 3H-UdR
incorporation into DNA of UM-SCC-14C cells than on that
of C26-10 cells.
Discussion
The antiproliferative effect of one of the FU analogues tested
in this study, 'cis-5-F-5,6-dihydro-6-methoxy-uracil' showed a
higher activity than FU in C26-10 (Figure 2). Most of the
other compounds also exhibited growth inhibitory capacities,
but higher concentrations were necessary to obtain effects
comparable to FU. The observation that the compounds
with a cis-configuration were generally more potent than
those with a trans-configuration is most probably related to
chemical stability against nucleophilic substitution of the C6-
group, which is higher for compounds with a trans-configur-
ation (Visser et al., 1992). In the cis-series chemically no
difference in substitution rate at C6 was observed for
analogues with a methoxy, ethoxy, n-propoxy or i-propoxy
group. So the decreasing antiproliferative effect in the cis-
series with increasing chain length might indicate the occur-
rence of steric hindrance of the longer alkoxy chain during
the approach of the C6-centre by the SH-group of the TS
enzyme.
The effect of the new analogues on their possible target,
TS, was investigated in two ways, the rescue of growth
inhibition by TdR, which would show that dTMP depletion
caused by inhibition of TS was a main factor for the anti-
tumour effect, and 3H-UdR incorporation into DNA, which
could reveal a change in TS activity caused by the drugs. The
TdR rescue was clear in the solid tumour cell lines in con-
trast to the lymphoblastoid cell lines. Besides the absence of
TdR rescue, the sensitivities of WI-L2 and WI-L2:Cl for FU
and the analogues were comparable despite the large differ-
ence in TS levels. These results are in accordance with find-
ings of Jackman et al. (1986) and O'Connor et al. (1992),
which show that in cell lines with very high TS, growth
inhibition, caused by FU, could not be reversed by TdR,
while reversal of growth inhibition, caused by FUdR, was
less in the overproducing lines than in the parent lines. The
latter phenomenon was explained to be related to an indirect
effect on the folate-dependent purine de novo synthesis, which
cannot be rescued by TdR alone, but requires the addition of
folinic acid and/or hypoxanthine. So unfortunately, the TS
overexpressing cell line was not an ideal model to study TdR
rescue of growth inhibition mediated by FU-based TS
inhibitors.
The incorporation of 3H-UdR was studied in two cell lines
(UM-SCC-14C and C26-10) with a 20-fold intrinsic differ-
ence in TS activity and a 4-fold difference in doubling time.
However, their IC50 for FU after 72 h exposure were com-
parable (about I ptM for both cell lines). On the other hand,
the short term effect of 1 4M FU on TS, measured after 3 h
drug exposure by 3H-UdR incorporation into DNA was
larger in UM-SCC-14C cells than in C26-10 cells. This might
be due to the high TS levels and the short doubling time of
the latter line.
Most of the newly synthesised compounds did not affect
the 3H-UdR incorporation into DNA of UM-SCC-14C cells
at equimolar concentration (1 fLM), but at IC50 concentrations
(equi-toxic) a significant reduction of 3H-UdR incorporation
was found for at least six of the nine analogues. The extent
of reduced 3H-UdR incorporation at equimolar concentra-
tions is an indication for the inhibition of TS and at least six
of these analogues appeared to cause inhibition of TS to a
certain extent in UM-SCC-14C cells. Although in C26-10 the
effects of FU and the three tested analogues on 3H-UdR
incorporation into DNA were less pronounced than in UM-
SCC-14C, cis-5-F-5,6-dihydro-6-methoxy-uracil(1) was the
most potent inhibitor of 3H-UdR incorporation and thereby
of TS, in both cell lines.
Apparently, cis-5-F-5, 6-dihydro-6-methoxy-uracil(l) is
cytotoxic without conversion to FU: for at equimolar con-
centration it had a higher growth inhibitory effect in C26-10
than FU. If the drug firstly had to be metabolised to FU, it
could never have been more toxic than FU. The structural
similarity of the analogues makes it seem reasonable to
assume that the other compounds exert their effect likewise,
but of course from the results alone it cannot be concluded
whether they are degraded (chemically or enzymatically to
FU) or are activated directly to active nucleotides.
So far we may conclude that cis-5-F-5,6-dihydro-6-meth-
oxy-uracil(1) is a potentially interestingly new FU analogue,
because it reduced 3H-UdR incorporation to a larger extent
than FU, in both tested cell lines. The compound was highly
active in the fast growing solid tumour cell line C26-10
(having a high intrinsic TS actvity), while it showed less
activity in the slower growing cell lines with lower TS
activity. Even in cells with a high acquired TS activity (due
to overproduction) a good activity of these pyrimidine based
compounds was achieved. These tests demonstrate that cis-5-
F-5,6-dihydro-6-methoxy-uracil(1) is a more active drug than
FU and a potent TS inhibitor. As a consequence in vivo
preclinical tests on antitumour effect and toxic side effects
will be performed to evaluate the efficacy of this new FU
analogue.
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